Literature DB >> 6404867

Supraglottic laryngeal carcinoma: an analysis of dose-time-volume factors in 410 patients.

A R Harwood, F A Beale, B J Cummings, T J Keane, D G Payne, W D Rider, E Rawlinson, T Elhakim.   

Abstract

Four hundred and ten patients with supraglottic laryngeal carcinoma treated with moderate dose radical radiotherapy with surgery for salvage (RRSS) were analyzed in detail to determine optimal dose-time-volume parameters to be used in the treatment of each stage of supraglottic carcinoma. In the RRSS group 41% are alive and well at 5 years, 38% died of their tumor and 21% of intercurrent disease. Presence or absence of nodal disease has a major impact on survival. Local control is approximately 70% in T1, T2N0 patients and approximately 50% in T3 and T4N0 patients. Seventeen percent of T1 and T2N0 patients failed in the initially negative neck. Ten major complications (2.4%) have been seen. Local control by irradiation was not influenced by dose or field size. Regional control in the initially negative neck was markedly increased with the use of larger irradiation field sizes. Field sizes of less than 7 X 7 cm resulted in an 18% neck failure rate as compared to 3% with larger field sizes (p = 0.00005). This particularly applied to early stage disease. As a result of the use of larger irradiation field sizes giving reduced neck failure rates, improvement in survival has been seen in early stage supraglottic patients. The results are compared with published results. There is no statistically significant dose response curve in any stage of supraglottic cancer over the dose range 1650-2300 ret. Optimal treatment factors for supraglottic cancer are discussed.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6404867     DOI: 10.1016/0360-3016(83)90289-4

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  8 in total

1.  The prognostic significance of race and survival from laryngeal carcinoma.

Authors:  M Roach; M Alexander; J L Coleman
Journal:  J Natl Med Assoc       Date:  1992-08       Impact factor: 1.798

Review 2.  Management of cervical lymph nodes in patients with head and neck cancer.

Authors:  G B Snow; P Patel; C R Leemans; R Tiwari
Journal:  Eur Arch Otorhinolaryngol       Date:  1992       Impact factor: 2.503

3.  [Reasons for the terms "radiosurgery" and "Gamma Knife"].

Authors:  K Hamm; G Surber
Journal:  HNO       Date:  2017-09       Impact factor: 1.284

Review 4.  Organ Preservation for Advanced Larynx Cancer: Issues and Outcomes.

Authors:  Arlene A Forastiere; Randal S Weber; Andy Trotti
Journal:  J Clin Oncol       Date:  2015-09-08       Impact factor: 44.544

5.  High-dose radiotherapy alone for patients with T4-stage laryngeal cancer.

Authors:  A Mucha-Małecka; K Składowski
Journal:  Strahlenther Onkol       Date:  2013-07-05       Impact factor: 3.621

6.  Cetuximab and Radiotherapy in Laryngeal Preservation for Cancers of the Larynx and Hypopharynx: A Secondary Analysis of a Randomized Clinical Trial.

Authors:  James Bonner; Jordi Giralt; Paul Harari; Sharon Spencer; Jeltje Schulten; Anwar Hossain; Shao-Chun Chang; Steve Chin; José Baselga
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2016-09-01       Impact factor: 6.223

7.  Radiotherapy in N0 head and neck cancer patients.

Authors:  J P Bataini
Journal:  Eur Arch Otorhinolaryngol       Date:  1993       Impact factor: 2.503

8.  The "gregorio marañon" hospital experience in the treatment of laryngeal carcinoma.

Authors:  M F Vega; T Martinez; B Scola; E Scola; S F Vega
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  1997-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.